On this page
What tesamorelin and ipamorelin doses do people report?
Two public accounts describe 1 mg tesamorelin with 300 mcg ipamorelin, and a later-stage blend containing 0.6 mg with 200 mcg. They describe different courses; they are not interchangeable versions of one protocol.
The accounts below are unverified first-person reports, not clinical dosing recommendations or testimonials for products featured on this site. Each ingredient is listed separately.
| Account | Tesamorelin | Ipamorelin | What the author actually reported |
|---|---|---|---|
| Completed three-month course | 1 mg daily | 300 mcg daily | Tesamorelin taken fasted in the morning; also creatine, a calorie deficit, and resistance/endurance training.1 |
| Seven-week update | 0.6 mg in the current blend | 200 mcg in that blend | Earlier stages used 1 mg, then 2 mg tesamorelin nightly. Also reported retatrutide. The original post did not separately restate the blend's frequency.2 |
These examples support reporting specific amounts, not a claim that everyone uses them. The tesamorelin dosage guide includes additional accounts of tesamorelin use and explains their weekly totals.
Why combine tesamorelin with ipamorelin?
The biological rationale is to stimulate two different receptor pathways involved in growth hormone release. That explains the pairing's appeal, but a plausible mechanism does not establish an effective combination dose.
Tesamorelin: the GHRH pathway
A growth hormone-releasing hormone analogue. It stimulates GHRH receptors and the pituitary's production and pulsatile release of endogenous GH.3
Ipamorelin: the ghrelin pathway
A growth hormone secretagogue acting through ghrelin receptors. FDA's pharmacology review describes its ability to stimulate GH release through this different pathway.4
Both aim to stimulate the body's own GH rather than supply injected HGH. The cited evidence does not establish that using this pair produces more muscle, greater fat loss, or fewer adverse effects than tesamorelin alone. Calling the combination “synergistic” requires direct comparative evidence, not just two different receptor names.
What research supports the combination?
The primary human studies cited here tested the ingredients separately. They establish GH-related activity under their study conditions, not the results of the community combinations above.
| Study | What it found | What it cannot establish |
|---|---|---|
| Tesamorelin in 13 healthy men | 2 mg daily for two weeks increased basal and pulsatile GH secretion and IGF-1.5 | An optimal long-term blend ratio or added benefit from ipamorelin. |
| Ipamorelin in healthy male volunteers | A dose-escalation study used 15-minute infusions and measured a GH response.6 | A daily subcutaneous bodybuilding schedule or efficacy when combined with tesamorelin. |
Route, formulation, population, and treatment duration matter. A laboratory GH response is a different endpoint from measured muscle growth or visceral-fat loss. For the established tesamorelin clinical outcomes, see benefits and research.
How long were the reported cycles, and when were the peptides taken?
One author completed about three months of daily co-use; the other described a changing course with a planned 12-week endpoint. The latter report was written around week seven, after earlier nightly tesamorelin stages before adding ipamorelin. A follow-up stated approximately three weeks at 0.6 mg, without separately specifying frequency or establishing that ipamorelin was used throughout those three weeks. The account does not document 12 completed weeks on the final blend.12
The morning account specifies fasted tesamorelin use, but does not give a measured fasting window or separately specify the ipamorelin injection time. Neither report compares morning with bedtime, daily with five-days-per-week use, or one break length with another. These reports therefore cannot settle which timing or cycle is best.
For arithmetic only, seven days at the first account's stated amounts totals 7 mg tesamorelin plus 2.1 mg ipamorelin. Changing frequency changes both totals; a planned cycle length does not establish how much was actually consumed.
What does a tesamorelin–ipamorelin blend ratio mean?
A ratio describes the relative amount of each ingredient. Convert both to the same unit before comparing: 300 mcg is 0.3 mg; 200 mcg is 0.2 mg. A combined total is not the amount of tesamorelin alone.
| Separate amounts | Tesamorelin : ipamorelin by mass | Combined peptide amount |
|---|---|---|
| 1 mg + 0.3 mg | 10 : 3 | 1.3 mg |
| 0.6 mg + 0.2 mg | 3 : 1 | 0.8 mg |
These are arithmetic comparisons of the reported amounts. The first account does not establish that both ingredients came in one vial. In a fixed-ratio mixture, changing the measured volume changes both ingredient amounts together; you cannot independently lower one ingredient by drawing less of the same mixture.
How many units or pen clicks is a blend dose?
You need each ingredient's concentration in mg/mL and the device's delivered volume. A U-100 syringe marking measures volume; a pen click depends on that device. Neither “2x blend,” a total vial weight, nor a ratio alone supplies the missing information.
The volume calculator can convert a specified amount using a verified concentration. For a blend, using its combined mg/mL as though it were the tesamorelin concentration gives the wrong tesamorelin amount. Check the second ingredient separately, too.
What results did the two authors actually report?
The three-month author reported 185 → 169 lb, improved sleep, and maintained gym strength. Visible changes became noticeable around month two; earlier effects included water retention. The same account described an approximately 500-calorie deficit, creatine, and substantial training. Its body-fat percentages were estimates, and it supplied no IGF-1 result.1 This does not isolate the combination's contribution to weight loss or prove new muscle growth.
The seven-week author reported IGF-1 rising from 189 to 373 ng/mL, satisfaction with body-composition changes, and mild nighttime hand numbness. The reported laboratory range was 74–239 ng/mL. The author also disclosed retatrutide use.2 Changing tesamorelin amounts and adding ipamorelin later prevent assigning the IGF-1 increase to the final blend alone. Retatrutide co-use also prevents isolating this pair's contribution to the reported body-composition changes.
What should you track beyond an IGF-1 increase?
Track the intended outcome, the laboratory response, and symptoms separately. Record the dates, separate ingredient amounts, other medications, diet and training changes alongside each result. That context makes a follow-up result interpretable.
IGF-1 is a downstream marker of GH signaling, not a direct measurement of how many HGH “units” the body produced. EGRIFTA's label calls for IGF-1 monitoring and glucose assessment before and during treatment. Persistent elevations, age-adjusted laboratory ranges, glucose and HbA1c need clinical interpretation.3
Tesamorelin's labeled concerns include fluid retention, joint symptoms, carpal tunnel symptoms, glucose intolerance, and hypersensitivity. Active malignancy, pregnancy, certain hypothalamic–pituitary disorders, and relevant hypersensitivity are contraindications. These are tesamorelin findings; they do not quantify this combination's risk.3 Persistent swelling or hand numbness warrants assessment. See side effects and monitoring.
What does FDA say about ipamorelin compounding?
FDA's current safety page lists ipamorelin acetate in Category 2 under the 503B interim compounding policy. It also appears in the page's withdrawn-nominations section. Those are compounding classifications; neither is approval of a tesamorelin–ipamorelin medicine.7
FDA identifies potential immune reactions associated with aggregation or peptide impurities, and insufficient safety information for certain injectable routes. It also cites serious adverse events, including deaths, in an intravenous gastric-motility study.7 Its detailed 2024 review says the relationship between those deaths and ipamorelin was unclear. That is not a measured death rate for a subcutaneous combination.4
EGRIFTA is a named tesamorelin medicine for excess abdominal fat in adults with HIV-associated lipodystrophy. That approval does not establish a blend's quality, preparation instructions, or benefit for general weight loss.3
Tesamorelin and ipamorelin FAQ
Does adding ipamorelin let you use less tesamorelin?
The cited accounts do not establish dose equivalence. A lower tesamorelin amount in one author's later blend is a reported change, not proof that ipamorelin replaced a specific amount of tesamorelin.
Can you put the two peptides in the same vial or syringe?
A report of co-use does not establish compatibility, sterility, or stability after mixing. A numerical ratio cannot supply those missing data. Preparation must be established for the exact formulation; EGRIFTA's instructions do not validate a homemade blend.
Is a blend the same as tesamorelin alone?
No. It introduces another active ingredient and, in a fixed mixture, another concentration to account for. A study of tesamorelin alone cannot determine the added ingredient's benefit or the combination's adverse-event rate.
Sources for the combination guide
- 1First-person three-month tesamorelin and ipamorelin account. Includes diet, training, and follow-up comments.
- 2First-person seven-week IGF-1 update. Changing tesamorelin amounts followed by a blend.
- 3EGRIFTA WR prescribing information. Mechanism, indication, contraindications, and monitoring.
- 4FDA ipamorelin review for the October 29, 2024 Pharmacy Compounding Advisory Committee. Pharmacology and safety evaluation; an advisory briefing, not a product approval.
- 5Stanley et al. Tesamorelin and endogenous GH pulsatility. A two-week study in 13 healthy men.
- 6Gobburu et al. Ipamorelin pharmacokinetics and GH response. Infusion study in healthy volunteers.
- 7FDA: bulk drug substances that may present significant safety risks. Current ipamorelin acetate entry and withdrawn-nomination distinction.